gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Breast cancer 1

Breast cancer
involved in the DNA damage response and DNA repair [RGD, Feb 2006] (from NCBI)
Top mentioned proteins: HAD, CAN, AGE, erbB-2, iMpact
Papers using Breast cancer antibodies
Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues
Kim Il-Han et al., In Journal of Experimental & Clinical Cancer Research : CR, 2000
... real-time (HMRT) quantitative PCR arrays, Cancer Survey real-time (CSRT 96-I) quantitative PCR arrays, and Human Breast Cancer real-time (BCRT I-V) qPCR arrays from OriGene (OriGene Technologies, Inc, Rockville, ...
UKCCCR guidelines for the welfare of animals in experimental neoplasia.
Ouchi Toru, In PLoS ONE, 1987
... IV) cancer stages (American Joint Committee on Cancer) were screened for LRP5wt and LRP5Δ (TissueScan Breast Cancer Tissue qPCR arrays BCRT101 and BCRT102, OriGene Technologies, INC ...
Papers on Breast cancer
ReCAP: Would Women with Breast Cancer Prefer to Receive an Antidepressant for Anxiety or Depression From Their Oncologist?
Holland et al., Chicago, United States. In J Oncol Pract, Feb 2016
QUESTIONS ASKED: Preferences of patients with breast cancer for provider-specific pharmacologic management of anxiety and depression are unknown.
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
Goldhirsch et al., Rimini, Italy. In J Clin Oncol, Feb 2016
We identified patient populations that remain at risk for an event at a median follow-up of 24 years from the diagnosis of operable breast cancer.
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Campbell et al., Newcastle, Australia. In J Clin Oncol, Feb 2016
PATIENTS AND METHODS: Cases (n = 2,000) were predominantly breast cancer-affected women referred to specialized Familial Cancer Centers on the basis of a strong family history of breast cancer and BRCA1 and BRCA2 wild type.
Inferring the Effects of Cancer Treatment: Divergent Results From Early Breast Cancer Trialists' Collaborative Group Meta-Analyses of Randomized Trials and Observational Data From SEER Registries.
Darby et al., Oxford, United Kingdom. In J Clin Oncol, Feb 2016
PURPOSE: To compare the effect of breast cancer radiotherapy as estimated from observational data with findings from randomized trials.
Differences in Multi-Modal Ultrasound Imaging between Triple Negative and Non-Triple Negative Breast Cancer.
Wu et al., Harbin, China. In Ultrasound Med Biol, Feb 2016
UNASSIGNED: The objective of this study was to identify multi-modal ultrasound imaging parameters that could potentially help to differentiate between triple negative breast cancer (TNBC) and non-TNBC.
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.
Neel et al., Toronto, Canada. In Cell, Feb 2016
Large-scale genomic studies have identified multiple somatic aberrations in breast cancer, including copy number alterations and point mutations.
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
Muss et al., Chapel Hill, United States. In J Clin Oncol, Feb 2016
PURPOSE: CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the treatment of patients age ≥ 65 with early-stage breast cancer.
Breast cancer brain metastases: biology and new clinical perspectives.
Wikman et al., Hamburg, Germany. In Breast Cancer Res, Dec 2015
Because of improvements in the treatment of patients with metastatic breast cancer, the development of brain metastases (BM) has become a major limitation of life expectancy and quality of life for many breast cancer patients.
New Findings on Breast Cancer Stem Cells: A Review.
Khazaei et al., Kermānshāh, Iran. In J Breast Cancer, Dec 2015
In 2003, with the isolation of cancer stem cells from the first solid tumor, breast cancer, and recognition of the tumorigenicity of these cells, this theory suggested that the main reason for therapy failure might be the presence of cancer stem cells.
Breast cancer resistance protein (BCRP)-containing circulating microvesicles contribute to chemoresistance in breast cancer.
Ma et al., Wuxi, China. In Oncol Lett, Dec 2015
Breast cancer resistance protein (BCRP), a marker of the multidrug-resistant phenotype, affects drug absorption, distribution, metabolism, and excretion in normal tissues.
Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 2.
Trukova et al., Zion, United States. In Integr Med (encinitas), Oct 2015
In Part 1 of the current review, the cardiotoxicity of standard breast cancer treatment was reviewed.
Sexual Minority Women's Health Behaviors and Outcomes After Breast Cancer.
Potter et al., Boston, United States. In Lgbt Health, Sep 2015
Our objective is to compare sexual minority women with breast cancer to a control sample of sexual minority women without cancer to identify differences in healthful lifestyle practices, weight, well-being and mental health.
Breast Cancer in Transgender Veterans: A Ten-Case Series.
Brown, Johnson City, United States. In Lgbt Health, Mar 2015
UNASSIGNED: All known cases of breast cancer in patients with a diagnosis consistent with transgender identification were identified in the Veterans Health Administration (1996-2013).
Micro-Ribonucleic Acid and Carcinogenesis: Breast Cancer as an Example.
Al-Moundhri et al., Muscat, Oman. In Oncol Rev, Mar 2015
MicroRNAs (miRNAs) are a class of small non-coding RNAs that have unique functions at post-transcriptional level (epigenetics).
Interleukin-17 Could Promote Breast Cancer Progression at Several Stages of the Disease.
Zhang et al., New Orleans, United States. In Mediators Inflamm, 2014
Metastatic disease accounts for more than 90% of deaths from breast cancer.
Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci.
Hay et al., Chicago, United States. In J Biol Chem, 2010
Akt prevents the translocation of BRCA1 to DNA damage foci and, thereby, inhibits the activation of Chk1 following DNA damage
Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells.
Bernard-Gallon et al., Clermont-Ferrand, France. In In Vivo, 2010
Promoter regions of Brca1 are modified by soy estrogens in prostate cancer cells.
Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland.
Hilakivi-Clarke et al., Washington, D.C., United States. In Breast Cancer Res Treat, 2009
Pubertal physical activity up-regulates tumor suppressor genes BRCA1, p53 and ER-beta, and reduced ER-alpha/ER-beta ratio in the mammary gland
Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.
Walker et al., Riverside, United States. In Mol Endocrinol, 2009
Data show that knockdown of BRCA1 inhibited nuclear translocation of the vitamin D receptor and the ability of 1alpha,25(OH)(2)D(3) to induce the VDR.
Tumor suppressor gene BRCA-1 is expressed by embryonic and adult neural stem cells and involved in cell proliferation.
Lindholm et al., Uppsala, Sweden. In J Neurosci Res, 2003
BRCA-1 is present in embryonic and adult rat neural stem cell (NSC) and that the expression is linked to NSC proliferation.
share on facebooktweetadd +1mail to friends